Analysts cheered on Merck's encouraging new quarterly report, which is highlighted by a 12 percent increase in revenue, with new and old drugs alike posting strong numbers. For the analysts, the report underscores Merck's progress with a five-year turnaround plan. And it marks the pharma giant's success in combating the effects of new generic competitors. Merck's stock jumped nine percent on the bullish news. Merck's Vioxx defense continued to take a bite out of profits, though. Merck increased its Vioxx reserve to $810 million.
- read the report on Merck from The Washington Post